Causes and factors related to dopamine agonist withdrawal in Parkinson′s disease
Background Although dopamine agonists (DAs) are useful in Parkinson′s disease (PD), they are not frequently used in elderly patients due to adverse effects. However, there is a lack of evidence because few elderly PD patients are enrolled in clinical trials. Aims of the study The aims of this study...
Gespeichert in:
| Veröffentlicht in: | Brain and behavior 2016-07, Vol.6 (7), p.n/a |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 7 |
| container_start_page | |
| container_title | Brain and behavior |
| container_volume | 6 |
| creator | Castro, Ester Suárez Santos‐García, Diego Deus Fonticoba, Teresa Expósito Ruíz, Irene Tuñas Gesto, Cintia Arribí, Mercedes Macías |
| description | Background
Although dopamine agonists (DAs) are useful in Parkinson′s disease (PD), they are not frequently used in elderly patients due to adverse effects. However, there is a lack of evidence because few elderly PD patients are enrolled in clinical trials.
Aims of the study
The aims of this study were to analyze the reasons of DA withdrawal (DAW) in a group of PD patients in clinical practice and to identify the related factors. Specifically, we studied the effect of age, comorbidity, and polypharmacy as potential risk factors for DAW.
Methods
A retrospective chart review of the follow‐up (from May, 2012 to March, 2015) of a subgroup of PD patients receiving a DA (n = 68; 60.3% males, 69.3 ± 9.2 years old) from a cohort (n = 150) previously studied in detail in 2012 was used to identify predictive factors of DAW.
Results
The DAW percentage was 18.2% (12/66; follow‐up of 690.2 ± 232.6 days). DAW causes were cognitive impairment (3), reduction therapy (3), hallucinations (2), dyskinesia (2), and excessive diurnal somnolence (2). Only a higher levodopa daily dose (HR 1.003; 95% CI 1.001–1.006; P = 0.044) was an independent predictor of DAW after adjustment for other explanatory variables.
Conclusions
The frequency of DAW was low. Advanced age alone is not a contraindication to the administration of DAs.
The frequency of dopamine agonist withdrawal in clinical practise is low and not related to age. A higher levodopa dose predicts higher risk of dopamine agonist withdrawal. |
| doi_str_mv | 10.1002/brb3.453 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4864043</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2287879993</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2973-3cf00048a4abb68672ccf7fe2b05d95eead69f63e54ff694af00a984ee8537043</originalsourceid><addsrcrecordid>eNp1kc9KxDAQxoMoKrrgIwS8eKm2SdokF0EX_4GgLHoO03ai0W6yJl0Xbz6Tj-ST2GVF9OBcZmB-880HHyF7RX5Y5Dk7qmPND0XJ18g2KyqWcSb1-q95i4xSesqHKgvBRL5JtphkQiqhtslkDPOEiYJvqYWmDzHRiB302NI-0DbMYOo8UngI3qWeLlz_2EZYQEedp7cQn51PwX--fyTauoSQcJdsWOgSjr77Drk_P7sbX2bXNxdX45PrrGFa8ow3drAkFAio60pVkjWNlRZZnZetLhGhrbStOJbC2koLGHDQSiCqkstc8B1yvNKdzesptg36PkJnZtFNIb6ZAM783Xj3aB7CqxGqEsP9ILD_LRDDyxxTb57CPPrBs2FMSSW11kvqYEU1MaQU0f58KHKzDMAsAzBDAAOardCF6_DtX86cTk75kv8C19yHdA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2287879993</pqid></control><display><type>article</type><title>Causes and factors related to dopamine agonist withdrawal in Parkinson′s disease</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via Wiley Online Library</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><creator>Castro, Ester Suárez ; Santos‐García, Diego ; Deus Fonticoba, Teresa ; Expósito Ruíz, Irene ; Tuñas Gesto, Cintia ; Arribí, Mercedes Macías</creator><creatorcontrib>Castro, Ester Suárez ; Santos‐García, Diego ; Deus Fonticoba, Teresa ; Expósito Ruíz, Irene ; Tuñas Gesto, Cintia ; Arribí, Mercedes Macías</creatorcontrib><description>Background
Although dopamine agonists (DAs) are useful in Parkinson′s disease (PD), they are not frequently used in elderly patients due to adverse effects. However, there is a lack of evidence because few elderly PD patients are enrolled in clinical trials.
Aims of the study
The aims of this study were to analyze the reasons of DA withdrawal (DAW) in a group of PD patients in clinical practice and to identify the related factors. Specifically, we studied the effect of age, comorbidity, and polypharmacy as potential risk factors for DAW.
Methods
A retrospective chart review of the follow‐up (from May, 2012 to March, 2015) of a subgroup of PD patients receiving a DA (n = 68; 60.3% males, 69.3 ± 9.2 years old) from a cohort (n = 150) previously studied in detail in 2012 was used to identify predictive factors of DAW.
Results
The DAW percentage was 18.2% (12/66; follow‐up of 690.2 ± 232.6 days). DAW causes were cognitive impairment (3), reduction therapy (3), hallucinations (2), dyskinesia (2), and excessive diurnal somnolence (2). Only a higher levodopa daily dose (HR 1.003; 95% CI 1.001–1.006; P = 0.044) was an independent predictor of DAW after adjustment for other explanatory variables.
Conclusions
The frequency of DAW was low. Advanced age alone is not a contraindication to the administration of DAs.
The frequency of dopamine agonist withdrawal in clinical practise is low and not related to age. A higher levodopa dose predicts higher risk of dopamine agonist withdrawal.</description><identifier>ISSN: 2162-3279</identifier><identifier>EISSN: 2162-3279</identifier><identifier>DOI: 10.1002/brb3.453</identifier><identifier>PMID: 27247848</identifier><language>eng</language><publisher>Los Angeles: John Wiley & Sons, Inc</publisher><subject>Activities of daily living ; Age ; Clinical medicine ; Cognitive ability ; Comorbidity ; Dementia ; Dopamine ; dopamine agonist ; Drug dosages ; Edema ; Hallucinations ; Parkinsons disease ; Parkinson′s disease ; Polypharmacy ; Studies ; tolerability ; Variables</subject><ispartof>Brain and behavior, 2016-07, Vol.6 (7), p.n/a</ispartof><rights>2016 The Authors. published by Wiley Periodicals, Inc.</rights><rights>2016. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2973-3cf00048a4abb68672ccf7fe2b05d95eead69f63e54ff694af00a984ee8537043</citedby><cites>FETCH-LOGICAL-c2973-3cf00048a4abb68672ccf7fe2b05d95eead69f63e54ff694af00a984ee8537043</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864043/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864043/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,866,887,1419,11569,27931,27932,45581,45582,46059,46483,53798,53800</link.rule.ids></links><search><creatorcontrib>Castro, Ester Suárez</creatorcontrib><creatorcontrib>Santos‐García, Diego</creatorcontrib><creatorcontrib>Deus Fonticoba, Teresa</creatorcontrib><creatorcontrib>Expósito Ruíz, Irene</creatorcontrib><creatorcontrib>Tuñas Gesto, Cintia</creatorcontrib><creatorcontrib>Arribí, Mercedes Macías</creatorcontrib><title>Causes and factors related to dopamine agonist withdrawal in Parkinson′s disease</title><title>Brain and behavior</title><description>Background
Although dopamine agonists (DAs) are useful in Parkinson′s disease (PD), they are not frequently used in elderly patients due to adverse effects. However, there is a lack of evidence because few elderly PD patients are enrolled in clinical trials.
Aims of the study
The aims of this study were to analyze the reasons of DA withdrawal (DAW) in a group of PD patients in clinical practice and to identify the related factors. Specifically, we studied the effect of age, comorbidity, and polypharmacy as potential risk factors for DAW.
Methods
A retrospective chart review of the follow‐up (from May, 2012 to March, 2015) of a subgroup of PD patients receiving a DA (n = 68; 60.3% males, 69.3 ± 9.2 years old) from a cohort (n = 150) previously studied in detail in 2012 was used to identify predictive factors of DAW.
Results
The DAW percentage was 18.2% (12/66; follow‐up of 690.2 ± 232.6 days). DAW causes were cognitive impairment (3), reduction therapy (3), hallucinations (2), dyskinesia (2), and excessive diurnal somnolence (2). Only a higher levodopa daily dose (HR 1.003; 95% CI 1.001–1.006; P = 0.044) was an independent predictor of DAW after adjustment for other explanatory variables.
Conclusions
The frequency of DAW was low. Advanced age alone is not a contraindication to the administration of DAs.
The frequency of dopamine agonist withdrawal in clinical practise is low and not related to age. A higher levodopa dose predicts higher risk of dopamine agonist withdrawal.</description><subject>Activities of daily living</subject><subject>Age</subject><subject>Clinical medicine</subject><subject>Cognitive ability</subject><subject>Comorbidity</subject><subject>Dementia</subject><subject>Dopamine</subject><subject>dopamine agonist</subject><subject>Drug dosages</subject><subject>Edema</subject><subject>Hallucinations</subject><subject>Parkinsons disease</subject><subject>Parkinson′s disease</subject><subject>Polypharmacy</subject><subject>Studies</subject><subject>tolerability</subject><subject>Variables</subject><issn>2162-3279</issn><issn>2162-3279</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kc9KxDAQxoMoKrrgIwS8eKm2SdokF0EX_4GgLHoO03ai0W6yJl0Xbz6Tj-ST2GVF9OBcZmB-880HHyF7RX5Y5Dk7qmPND0XJ18g2KyqWcSb1-q95i4xSesqHKgvBRL5JtphkQiqhtslkDPOEiYJvqYWmDzHRiB302NI-0DbMYOo8UngI3qWeLlz_2EZYQEedp7cQn51PwX--fyTauoSQcJdsWOgSjr77Drk_P7sbX2bXNxdX45PrrGFa8ow3drAkFAio60pVkjWNlRZZnZetLhGhrbStOJbC2koLGHDQSiCqkstc8B1yvNKdzesptg36PkJnZtFNIb6ZAM783Xj3aB7CqxGqEsP9ILD_LRDDyxxTb57CPPrBs2FMSSW11kvqYEU1MaQU0f58KHKzDMAsAzBDAAOardCF6_DtX86cTk75kv8C19yHdA</recordid><startdate>201607</startdate><enddate>201607</enddate><creator>Castro, Ester Suárez</creator><creator>Santos‐García, Diego</creator><creator>Deus Fonticoba, Teresa</creator><creator>Expósito Ruíz, Irene</creator><creator>Tuñas Gesto, Cintia</creator><creator>Arribí, Mercedes Macías</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M2M</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>201607</creationdate><title>Causes and factors related to dopamine agonist withdrawal in Parkinson′s disease</title><author>Castro, Ester Suárez ; Santos‐García, Diego ; Deus Fonticoba, Teresa ; Expósito Ruíz, Irene ; Tuñas Gesto, Cintia ; Arribí, Mercedes Macías</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2973-3cf00048a4abb68672ccf7fe2b05d95eead69f63e54ff694af00a984ee8537043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Activities of daily living</topic><topic>Age</topic><topic>Clinical medicine</topic><topic>Cognitive ability</topic><topic>Comorbidity</topic><topic>Dementia</topic><topic>Dopamine</topic><topic>dopamine agonist</topic><topic>Drug dosages</topic><topic>Edema</topic><topic>Hallucinations</topic><topic>Parkinsons disease</topic><topic>Parkinson′s disease</topic><topic>Polypharmacy</topic><topic>Studies</topic><topic>tolerability</topic><topic>Variables</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Castro, Ester Suárez</creatorcontrib><creatorcontrib>Santos‐García, Diego</creatorcontrib><creatorcontrib>Deus Fonticoba, Teresa</creatorcontrib><creatorcontrib>Expósito Ruíz, Irene</creatorcontrib><creatorcontrib>Tuñas Gesto, Cintia</creatorcontrib><creatorcontrib>Arribí, Mercedes Macías</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Free Content</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Brain and behavior</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Castro, Ester Suárez</au><au>Santos‐García, Diego</au><au>Deus Fonticoba, Teresa</au><au>Expósito Ruíz, Irene</au><au>Tuñas Gesto, Cintia</au><au>Arribí, Mercedes Macías</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Causes and factors related to dopamine agonist withdrawal in Parkinson′s disease</atitle><jtitle>Brain and behavior</jtitle><date>2016-07</date><risdate>2016</risdate><volume>6</volume><issue>7</issue><epage>n/a</epage><issn>2162-3279</issn><eissn>2162-3279</eissn><abstract>Background
Although dopamine agonists (DAs) are useful in Parkinson′s disease (PD), they are not frequently used in elderly patients due to adverse effects. However, there is a lack of evidence because few elderly PD patients are enrolled in clinical trials.
Aims of the study
The aims of this study were to analyze the reasons of DA withdrawal (DAW) in a group of PD patients in clinical practice and to identify the related factors. Specifically, we studied the effect of age, comorbidity, and polypharmacy as potential risk factors for DAW.
Methods
A retrospective chart review of the follow‐up (from May, 2012 to March, 2015) of a subgroup of PD patients receiving a DA (n = 68; 60.3% males, 69.3 ± 9.2 years old) from a cohort (n = 150) previously studied in detail in 2012 was used to identify predictive factors of DAW.
Results
The DAW percentage was 18.2% (12/66; follow‐up of 690.2 ± 232.6 days). DAW causes were cognitive impairment (3), reduction therapy (3), hallucinations (2), dyskinesia (2), and excessive diurnal somnolence (2). Only a higher levodopa daily dose (HR 1.003; 95% CI 1.001–1.006; P = 0.044) was an independent predictor of DAW after adjustment for other explanatory variables.
Conclusions
The frequency of DAW was low. Advanced age alone is not a contraindication to the administration of DAs.
The frequency of dopamine agonist withdrawal in clinical practise is low and not related to age. A higher levodopa dose predicts higher risk of dopamine agonist withdrawal.</abstract><cop>Los Angeles</cop><pub>John Wiley & Sons, Inc</pub><pmid>27247848</pmid><doi>10.1002/brb3.453</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2162-3279 |
| ispartof | Brain and behavior, 2016-07, Vol.6 (7), p.n/a |
| issn | 2162-3279 2162-3279 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4864043 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via Wiley Online Library; Wiley Online Library (Open Access Collection); PubMed Central |
| subjects | Activities of daily living Age Clinical medicine Cognitive ability Comorbidity Dementia Dopamine dopamine agonist Drug dosages Edema Hallucinations Parkinsons disease Parkinson′s disease Polypharmacy Studies tolerability Variables |
| title | Causes and factors related to dopamine agonist withdrawal in Parkinson′s disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T04%3A55%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Causes%20and%20factors%20related%20to%20dopamine%20agonist%20withdrawal%20in%20Parkinson%E2%80%B2s%20disease&rft.jtitle=Brain%20and%20behavior&rft.au=Castro,%20Ester%20Su%C3%A1rez&rft.date=2016-07&rft.volume=6&rft.issue=7&rft.epage=n/a&rft.issn=2162-3279&rft.eissn=2162-3279&rft_id=info:doi/10.1002/brb3.453&rft_dat=%3Cproquest_pubme%3E2287879993%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2287879993&rft_id=info:pmid/27247848&rfr_iscdi=true |